research Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects
The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
Search
for
Sort by
Research
30 / 50 results 
research Topical Application of Anti-Cancer Drug Bortezomib Stimulates Proliferation of Follicular Cells and Induces Expression of Hair Keratins via GATA-3 Transcription Factor
Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
research Case Report: Two Instances of Drug Eruption Caused by Bortezomib Presenting as Multiple Plaques on the Trunk
Bortezomib chemotherapy can cause temporary skin rashes.
research Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Cutis Verticis Gyrata Heralding a Diagnosis of Primary Systemic Amyloidosis in a Patient with Cardioembolic Stroke
Recognizing CVG can help diagnose systemic amyloidosis early.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research 69-Year-Old Man With Dysuria and Right Lower Abdominal Pain
The man was diagnosed with stage III multiple myeloma and treated to improve kidney function.
research Role of Liposomal Anthracyclines in the Treatment of Multiple Myeloma
Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
research A Novel Mutation in the FERMT1 Gene in a Spanish Family with Kindler’s Syndrome
Researchers found a new mutation in the FERMT1 gene in a Spanish family with Kindler syndrome.
research Anticancer Drugs in Surface Waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Overview of Common, Rare, and Atypical Manifestations of Cutaneous Lupus Erythematosus and Histopathological Correlates
The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.
research Chemotherapy-Induced Alopecia Management: Clinical Experience and Practical Advice
The conclusion is to use scalp cooling, gentle hair care, and treatments like minoxidil for managing hair loss from chemotherapy, and stresses the need for more research and collaboration in this area.
research Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal, and Prostate Cancer
Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
research Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
research Dihydrotestosterone Induces p27 Degradation via Direct Binding with SKP2 in Ovarian and Breast Cancer
Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
research Sulforaphane Promotes Murine Hair Growth by Accelerating the Degradation of Dihydrotestosterone
Sulforaphane may help with hair growth by breaking down a hormone that causes hair loss.
research Drug Eruptions in Dermatology
Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.
research Bendamustine: An Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
research Sulforaphane, L-Menthol, and Dexpanthenol as a Novel Active Cosmetic Ingredient Composition for Relieving Hair Loss Symptoms
A mix of sulforaphane, L-menthol, and dexpanthenol could help increase hair growth and reduce hair loss.
research Partial Proteasome Inhibitors Induce Hair Follicle Growth by Stabilizing Beta-Catenin
Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Cutaneous Drug Reactions
Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.
research Novel Advances of Histone Modification in Inflammatory Skin Diseases and Related Treatment Methods
Histone modification is key in treating chronic inflammatory skin diseases.
research Robotic Hair Transplantation – Artificial Intelligence Plus Human Touch
Robotic hair transplantation with AI offers more reliable, precise, and efficient hair restoration.
research The Role of 3Rs in the Age of One Health: Where We Are and Where We’re Going
Innovative methods are reducing animal testing and improving biomedical research.
research Achievement of Low Disease Activity in Lupus Patients Treated with Belimumab Is Independent of Serologic Status at Baseline: A Real-Life Observational Study
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.